SEC Company Response from Entero Therapeutics, Inc. (GRDX) (CIK 0001604191) (GRDX) — Aug 12, 2016
Entero Therapeutics, Inc. (GRDX) (CIK 0001604191)
Date: Aug. 12, 2016 · CIK: 0001604191 · Accession: 0001415889-16-006784
AI Filing Summary & Sentiment
File numbers found in text: 333-212511
Show Raw Text
CORRESP
1
filename1.htm
azrxcorresp_aug122016.htm
AZURRX BIOPHARMA, INC.
760 Parkside Avenue
Downstate Biotechnology Incubator, Suite 217
Brooklyn, New York 11226
August 12, 2016
VIA EDGAR
Securities and Exchange Commission
100 F Street, NE
Washington, D.C. 20549
Re:
AzurRx BioPharma, Inc. (the “Company”)
Registration Statement on Form S-1
File No. 333-212511
Ladies and Gentlemen:
Reference is made to the Company’s letter, filed as correspondence via EDGAR on August 11, 2016, in which the Company requested acceleration of the effective date of the above-referenced Registration Statement to August 12, 2016, at 5:00 p.m., or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. We hereby withdraw such request for acceleration of the effective date.
Very truly yours,
AZURRX BIOPHARMA, INC.
By: /s/ Johan M. (Thijs) Spoor
Name: Johan M. (Thijs) Spoor
Title: President and Chief Executive Officer